Evidence map›Paper›PMID 25086031›Full record

ArticleThe Journal of biological chemistry2014

Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cells.

Xin Zhao, Susan A Rotenberg

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Borg family of Cdc42 effector proteins Cdc42EP1-5.Biochemical Society transactions · 2016
    Review
  6. A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xin ZhaoFrom the Department of Chemistry and Biochemistry, Queens College, Flushing, New York 11367 and The Graduate Center, The City University of New York, New York, New York 10016.
Susan A RotenbergFrom the Department of Chemistry and Biochemistry, Queens College, Flushing, New York 11367 and Susan.Rotenberg@qc.cuny.edu.
Queens College, CUNY · USThe Graduate Center, CUNY · US

Funding

Protein Kinase C Substrates in Human Breast CancerR15CA125632 · NCI · QUEENS COLLEGE · PI ROTENBERG, SUSAN A. · 2007 to 2013
$930k
NCI NIH HHS CA125632NCI NIH HHS R15 CA125632
6 · The paper itself

Abstract

Cdc42 effector protein-4 (CEP4) was recently identified by our laboratory to be a substrate of multiple PKC isoforms in non-transformed MCF-10A human breast cells. The significance of phosphorylated CEP4 to PKC-stimulated motility of MCF-10A cells was evaluated. Single site mutants at Ser residues embedded in potential PKC consensus sites (Ser(18), Ser(77), Ser(80), and Ser(86)) were individually replaced with Asp residues to simulate phosphorylation. Following expression in weakly motile MCF-10A cells, the S18D and S80D mutants each promoted increased motility, and the double mutant (S18D/S80D) produced a stronger effect. MS/MS analysis verified that Ser(18) and Ser(80) were directly phosphorylated by PKCα in vitro. Phosphorylation of CEP4 severely diminished its affinity for Cdc42 while promoting Rac activation and formation of filopodia (microspikes). In contrast, the phosphorylation-resistant double mutant S18A/S80A-CEP4 blocked CEP4 phosphorylation and inhibited motility of MCF-10A cells that had been stimulated with PKC activator diacylglycerol lactone. In view of the dissociation of phospho-CEP4 from Cdc42, intracellular binding partners were explored by expressing each CEP4 double mutant from a tandem affinity purification vector followed by affinity chromatography, SDS-PAGE, and identification of protein bands evident only with S18D/S80D-CEP4. One binding partner was identified as tumor endothelial marker-4 (TEM4; ARHGEF17), a guanine nucleotide exchange factor that is involved in migration. In motile cells expressing S18D/S80D-CEP4, knockdown of TEM4 inhibited both Rac activation and motility. These findings support a model in which PKC-mediated phosphorylation of CEP4 at Ser(18) and Ser(80) causes its dissociation from Cdc42, thereby increasing its affinity for TEM4 and producing Rac activation, filopodium formation, and cell motility.

Indexed as

BreastBreast NeoplasmsCell Line, TumorCell MovementCytoskeletal ProteinsElectrophoresis, Polyacrylamide GelFemaleGTP-Binding Protein RegulatorsHumansPhosphorylationProtein Kinase CPseudopodiarho GTP-Binding ProteinsRNA-Binding ProteinsSignal TransductionCDC42EP4 protein, humanCytoskeletal ProteinsGTP-Binding Protein RegulatorsProtein Kinase Crho GTP-Binding ProteinsRNA-Binding ProteinsActinBreast CancerGTPaseGuanine Nucleotide Exchange Factor (GEF)Protein Kinase C, Cdc42, Rac, MutantProtein PhosphorylationProtein Purification

Identifiers

PMID25086031
PMCPMC4162185
OpenAlexW2094677107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.